Q-omics provides the consensus-scored DNAH10OS profile across patient tissues and cancer cell-line models. DNAH10OS expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, DNAH10OS is differentially expressed in 10, with the highest sampling consensus in BRCA. Additionally, DNAH10OS RNA expression shows 18,686 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUSC, BRCA, and THYM as cancer lineages where DNAH10OS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNAH10OS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNAH10OS survival associations across molecular data types. DNAH10OS RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNAH10OS RNA expression–survival associations across cancer types. High DNAH10OS expression shows unfavorable associations in LUSC, CESC and UVM, but favorable associations in UCS, PAAD and BLCA. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for DNAH10OS RNA expression.
This table summarizes DNAH10OS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for DNAH10OS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNAH10OS shows lower tumor expression in THCA, LUSC and KIRC and higher tumor expression in BRCA, LIHC and CHOL. The BRCA box plot shows higher DNAH10OS RNA expression in tumor versus normal tissue (log2 FC = +0.568, t-test p < 0.001).
This table shows molecular features associated with DNAH10OS in patient tissues and cancer cell lines. In patient samples, DNAH10OS shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, DNAH10OS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma.
